MGAT5 and neoplasm: Because SSA was demonstrated to efficiently decrease MGAT5-triggered anoikis resistance in vivo as well as in vivo, it is highly plausible that SSA can be developed as therapeutics, as itself or an engineered form, for cancer patients who have anoikis-resistant, circulating or dormant tumor cells in the circulatory system.